© 1996 Oxford University Press
research-article |
The Epidemic of Visceral Leishmaniasis in Western Upper Nile, Southern Sudan: Course and Impact from 1984 to 1994
*MSF (Médecins sans Frontières)—Holland PO Box 10014, 1001 EA Amsterdam The Netherlands.
**(Formerly: MSF-Holland) Centre for Development Studies, University of Wales Swansea Swansea SA2 8PP, UK.
Healthnet International PO Box 10706, 1001 ES, Amsterdam, The Netherlands.
BACKGROUND: Although endemic in parts of southern Sudan, visceral leishmaniasis (VL) had not been reported in Western Upper Nile (WUN) until an epidemic was confirmed in 1989. A combination of circumstances created conditions for transmission among a population of mainly Nuer and Dinka people who had no immunity. The civil war which restarted In 1983 has been a major contributing cause and continues to hinder provision of treatment, data collection and control measures.
METHODS: Since the first of three clinics to treat VL was established in WUN in 1989, data on the epidemic and mortality have been collected in seven retrospective surveys of villages and among patients. Adults were interviewed about surviving family members and those who had died since the epidemic came. Survey death rates are used here to estimate mortality from VL and ‘excess mortality’ above expected levels.
RESULTS: The surveys found high mortality at all ages and suggest an overall death rate of 38–57% since the epidemic started in 1984, and up to 70% in the most affected areas. Both methods of estimation suggest that around 100 000 deaths, among about 280 000 people in the epidemic area, might be attributable to VL.
CONCLUSIONS: This continuing epidemic has shown that VL can cause high mortality in an outbreak with astonishingly high infection rates. Population movement has been a major factor in transmission and poor nutntional status has probably contributed to the risk of clinical infection. Although over 17 000 people have been successfully treated for VL at the clinics in WUN, the disease is likely to become endemic there.
Keywords visceral leishmaniasis, kala azar, Sudan, mortality, peidemic
Revised 1 January 1996
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Alvar, P. Aparicio, A. Aseffa, M. Den Boer, C. Canavate, J.-P. Dedet, L. Gradoni, R. Ter Horst, R. Lopez-Velez, and J. Moreno The Relationship between Leishmaniasis and AIDS: the Second 10 Years Clin. Microbiol. Rev., April 1, 2008; 21(2): 334 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Alvar, S. Bashaye, D. Argaw, I. Cruz, P. Aparicio, A. Kassa, G. Orfanos, F. Parreno, O. Babaniyi, N. Gudeta, et al. Kala-Azar Outbreak in Libo Kemkem, Ethiopia: Epidemiologic and Parasitologic Assessment Am J Trop Med Hyg, August 1, 2007; 77(2): 275 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Melaku, S. M. Collin, K. Keus, F. Gatluak, K. Ritmeijer, and R. N. Davidson Treatment of Kala-Azar in Southern Sudan using a 17-Day Regimen of Sodium Stibogluconate Combined with Paromomycin: A Retrospective Comparison with 30-Day Sodium Stibogluconate Monotherapy Am J Trop Med Hyg, July 1, 2007; 77(1): 89 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Elshafie, E. Ahlin, L. Mathsson, G. ElGhazali, and J. Ronnelid Circulating Immune Complexes (IC) and IC-Induced Levels of GM-CSF Are Increased in Sudanese Patients with Acute Visceral Leishmania donovani Infection Undergoing Sodium Stibogluconate Treatment: Implications for Disease Pathogenesis J. Immunol., April 15, 2007; 178(8): 5383 - 5389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. BERN, J. AMANN, R. HAQUE, R. CHOWDHURY, M. ALI, K. M. KURKJIAN, L. VAZ, Y. WAGATSUMA, R. F. BREIMAN, W. E. SECOR, et al. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in bangladesh. Am J Trop Med Hyg, October 1, 2006; 75(4): 744 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. M. Roberts Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment Br. Med. Bull., July 17, 2006; 75-76(1): 115 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. AHLUWALIA, C. BERN, C. COSTA, T. AKTER, R. CHOWDHURY, M. ALI, D. ALAM, E. KENAH, J. AMANN, M. ISLAM, et al. VISCERAL LEISHMANIASIS: CONSEQUENCES OF A NEGLECTED DISEASE IN A BANGLADESHI COMMUNITY Am J Trop Med Hyg, December 1, 2003; 69(6): 624 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-E. A. ELNAIEM, J. SCHORSCHER, A. BENDALL, V. OBSOMER, M. E. OSMAN, A. M. MEKKAWI, S. J. CONNOR, R. W. ASHFORD, and M. C. THOMSON RISK MAPPING OF VISCERAL LEISHMANIASIS: THE ROLE OF LOCAL VARIATION IN RAINFALL AND ALTITUDE ON THE PRESENCE AND INCIDENCE OF KALA-AZAR IN EASTERN SUDAN Am J Trop Med Hyg, January 1, 2003; 68(1): 10 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Brendle, A. Outlaw, A. Kumar, D. W. Boykin, D. A. Patrick, R. R. Tidwell, and K. A. Werbovetz Antileishmanial Activities of Several Classes of Aromatic Dications Antimicrob. Agents Chemother., March 1, 2002; 46(3): 797 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Stager, D. F. Smith, and P. M. Kaye Immunization with a Recombinant Stage-Regulated Surface Protein from Leishmania donovani Induces Protection Against Visceral Leishmaniasis J. Immunol., December 15, 2000; 165(12): 7064 - 7071. [Abstract] [Full Text] [PDF]
|
|